Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$KLGDF The Insiders collectively purchased a total of $239,000 of the Offering
$KALO.V
https://kalogoldcorp.com/2024/07/22/kalo-gold-announces-closing-of-1573663-oversubscribed-first-tranche-of-non-brokered-private-placement-and-increases-offering-to-1800000/
$klgdf KALO.v is a gold exploration company with a talented team and lots of property in Fiji
With a tiny tiny market cap and gold trading above $2300, it seems like this one has room to run
This stock is an amazing turnaround story- looks like there is a lot going on with the company and talk of revenues is giving me a lot of hope and excitement. I'm glad to be a long term HODLer. Any of the other OLD longs around these days? The spzi dream lives.
thank you, i'll check them out.
Thanks for the responses. I'll look into all of them.
On mine, I think $ABOS continues to strengthen as they get through Phase II with subsequent data potentially causing explosive growth. They are well capitalized.
$PMN is my favorite AD therapeutic (based on the scientific data), but the company still needs to raise their Phase 2 capital which will cause dilution
$KLGDF has a miniscule market cap and a lot of promising property. But no major hits yet. If they do though, it will go crazy. They'll need to finance of course.
Happy New Year and good luck!
What are the top 3 penny stocks I should buy for the new year? And why? (o/s, financing needs until profitability, market size) TIA
I'm holding $KLGDF, $ABOS, and $PMN looking to diversify
$KLGDF tiny market cap, golden opportunity. Might run in 2024 if they discover more gold at their huge site in Fiji. https://kalogoldcorp.com/2023/12/11/exploration-update-of-vatu-aurum-gold-project-fiji/
Gold seems to be heating up in general. https://kingworldnews.com/gold-very-close-to-another-major-breakout-as-we-head-into-2024/
a golden 2024 for $KLGDF ?
https://kingworldnews.com/gold-very-close-to-another-major-breakout-as-we-head-into-2024/
$KLGDF gonna get lit in 2024?
https://kingworldnews.com/gold-very-close-to-another-major-breakout-as-we-head-into-2024/
$KLGDF think gold in 2024 https://kingworldnews.com/gold-very-close-to-another-major-breakout-as-we-head-into-2024/
gold ready to roll
$KLGDF could have a good 2024
https://kingworldnews.com/gold-very-close-to-another-major-breakout-as-we-head-into-2024/
$KLGDF gonna be lit if they hit in 2024
Here is their corporate update. Market cap is tiny. Property is large and promising.
https://kalogoldcorp.com/2023/12/11/exploration-update-of-vatu-aurum-gold-project-fiji/
Kalo Gold $KLGDF gonna be lit if they hit in 2024
https://kalogoldcorp.com/2023/12/11/exploration-update-of-vatu-aurum-gold-project-fiji/
$KLGDF gonna be lit if they hit in 2024
https://kalogoldcorp.com/2023/12/11/exploration-update-of-vatu-aurum-gold-project-fiji/
KLGDF has upside in flight to gold
KLGDF
tiny market cap
found more gold
not much liquidity
ran hard last time it went up
could run really hard in flight to gold
Gold market heating up... KLGDF is a going to be a beanstalk. Tiny market cap. New gold discovery. Poor liquidity. Could run to 10 cents plus in a heartbeat on safe haven plays.
KLGDF could rip, tiny market cap and just discovered gold at Fiji site
https://kalogoldcorp.com/2023/09/27/kalo-discovers-new-epithermal-gold-and-copper-mineralization-at-vatu-aurum-gold-project-fiji/
KLGDF seems like it has potential
New gold discovery, price near ATL, and tiny market cap
Looking at KLDGF this week- tiny market cap, capable staff, efficient operation. Just announced new gold discovery.
https://kalogoldcorp.com/2023/09/27/kalo-discovers-new-epithermal-gold-and-copper-mineralization-at-vatu-aurum-gold-project-fiji/
Is KLGDF worth a look? tiny market cap, just announced new gold discovery
I first heard about them on KWN last year and have been watching since. Seems like a technically solid team and again, an efficient operation with tiny market cap.
https://kalogoldcorp.com/2023/09/27/kalo-discovers-new-epithermal-gold-and-copper-mineralization-at-vatu-aurum-gold-project-fiji/
KLGDF has my attention at the moment... new gold discovery just announced, and ridiculously small market cap.
Could run if volume ticks up.
https://kalogoldcorp.com/2023/09/27/kalo-discovers-new-epithermal-gold-and-copper-mineralization-at-vatu-aurum-gold-project-fiji/
Looking closely at KLGDF ... just discovered gold and some silver in Fiji. Tiny market cap, exploratory stage. Seems like a good team though. and again, miniscule market cap. seems like she could run on this news if the volume popped this week.
https://kalogoldcorp.com/2023/09/27/kalo-discovers-new-epithermal-gold-and-copper-mineralization-at-vatu-aurum-gold-project-fiji/
Is KLGDF the real deal? Just discovered gold, and ridiculously small market cap. I heard about them through KingWorldNews last year and have been watching the price fall for some time. With the news, seems like a good time to pounce.
https://kalogoldcorp.com/2023/09/27/kalo-discovers-new-epithermal-gold-and-copper-mineralization-at-vatu-aurum-gold-project-fiji/
What do you think of KLGDF? Tiny market cap, just discovered new gold deposit. Funds operations through pretty minor financing, a few mil per year or so. The managers seem to know their technical area well.
https://kalogoldcorp.com/2023/09/27/kalo-discovers-new-epithermal-gold-and-copper-mineralization-at-vatu-aurum-gold-project-fiji/
I think the Dixie Chicks have a song about that guy, haha
$ARFXF on fire after biogen news
still a long way to run
ProMIS Neurosciences makes a more selective and specific antibody than Biogen's aducanumab. Aducanumab is limited by brain swelling effects but has shown some clinical benefit, hence FDA approval today and a boost in their market cap by about $10-15 BILLION in just an hour.
ARFXF (ProMIS) makes PMN310 which can be dosed at higher levels. The company has been pre-phase I for a while, and shareholders were told that PHI funding was contingent on FDA approval of aducanumab.
Here's the real kicker... PMN's market cap is only $60M... which is peanuts compared to the market opportunity.
$ARFXF
glta
$ARFXF on fire after biogen news
still a long way to run
ProMIS Neurosciences makes a more selective and specific antibody than Biogen's aducanumab. Aducanumab is limited by brain swelling effects but has shown some clinical benefit, hence FDA approval today and a boost in their market cap by about $10-15 BILLION in just an hour.
ARFXF (ProMIS) makes PMN310 which can be dosed at higher levels. The company has been pre-phase I for a while, and shareholders were told that PHI funding was contingent on FDA approval of aducanumab.
Here's the real kicker... PMN's market cap is only $60M... which is peanuts compared to the market opportunity.
$ARFXF
glta
$ARFXF on fire after biogen news
still a long way to run
ProMIS Neurosciences makes a more selective and specific antibody than Biogen's aducanumab. Aducanumab is limited by brain swelling effects but has shown some clinical benefit, hence FDA approval today and a boost in their market cap by about $10-15 BILLION in just an hour.
ARFXF (ProMIS) makes PMN310 which can be dosed at higher levels. The company has been pre-phase I for a while, and shareholders were told that PHI funding was contingent on FDA approval of aducanumab.
Here's the real kicker... PMN's market cap is only $60M... which is peanuts compared to the market opportunity.
$ARFXF
glta
$ARFXF on fire after biogen news
still a long way to run
ProMIS Neurosciences makes a more selective and specific antibody than Biogen's aducanumab. Aducanumab is limited by brain swelling effects but has shown some clinical benefit, hence FDA approval today and a boost in their market cap by about $10-15 BILLION in just an hour.
ARFXF (ProMIS) makes PMN310 which can be dosed at higher levels. The company has been pre-phase I for a while, and shareholders were told that PHI funding was contingent on FDA approval of aducanumab.
Here's the real kicker... PMN's market cap is only $60M... which is peanuts compared to the market opportunity.
$ARFXF
glta
I'm taking the liberty to revise the already weird spzi PR (see below) because I am bored and needed a chuckle. I still think we are in a reverse merger situation.
[Please note, this is laced with satire. this is a doctored version of the press release, for comic relief. Though there is perhaps a little truth behind each joke. THIS IS NOT A REAL PRESS RELEASE!!!]
Clearwater, Florida, Where Paul Strickland has been vacationing for the last ten years. - SPOOZ, INC. (yes, we really named the company spooz) is pleased to announce that it has commenced the process to resurrect Spooz, and by resurrect, we mean do nothing, because it was never actually commercialized. The Company has been dormant since 2008 because we were too lazy to do the closeout paperwork, and we always hoped a day like today would come when our lack of follow through would finally pay off.
On January 11, 2021, ten thousand (10,000) shares of SPZI traded in the public marketplace. This event, which involved a whopping $1 trade at the impressive pps of $0.0001, incentivized the Company’s former management, including its former Chairman and CEO, Paul D. Strickland, Jr. and Director and former COO, Errol Stone, as well as the world, to not even notice. However, we are going back in time with this stealthy low-budget PR so that we can claim that at that time we decided to bring Spooz, Inc., current and compliant with any and all federal and state regulatory agencies. That effort is underway and actually did not start until someone started buying a boatload of shares out of nowhere, but we have to pretend like we were dusting off the books before that crazy buying started to avoid suspicion, despite the claims above being completely moronic.
Since January 11, 2021, significant trading volume occurred for SPZI shares, and on April 29, 2021, the volume of shares traded approached 2.2 billion, and that's when we noticed that old spzi shareholders had stalked us down and started bombarding us with emails (darn that internet and people's memory/scars). As of this date (what day is it?), SPZI continues to exhibit significant volume on a daily basis, and I bought and obliterated some champagne yesterday. We are writing this PR to clearly communicate that the Company and its former Officers and Directors have in no way participated in, organized, directed or executed any trading activity in SPZI whatsoever and have derived no benefit from such trading activity, and further, disavow any knowledge, including the identities of the parties engaging in such activity. However, we have mentioned our group of old failed but financially intact shell candidates to every private business owner we've ever met over the last 10 years. And please note that we used the word 'disavow', which basically means we deny it, but that we might be lying. And okay, it is a little dubious to say that we derived no benefit from this trading activity, since we literally just stated that such trading activity allowed us to reopen our doors and encouraged us to dust off our books.
Spooz, Inc., has retained its original VAPORware technology in the form of all technical architecture (they were literally built into excel files because we suck at coding) and specifications for SpoozToolz which must be updated so they might actually be useful. Spooz former Officers and Directors believe the SpoozToolz technology to be as relevant in today’s marketplace as when originally developed, especially given that it was not actually ever relevant, and considering the advent of electronic trading of digital assets (including, but not limited to, cryptocurrencies, where we just lost 50% of our investments in one week due to Elon). Mr. Strickland stated, “I am exceedingly pleased that we may have an opportunity to complete what we began at Spooz years ago and look forward to an exciting future for the Company and its loyal and patient and gullible shareholders. However, there can be no assurances, expressed or implied, that we will be able to accomplish our goals.” That's jargon for "we have no intent of operating this company, but we want to get the financials current so the the real business people that know how to close deals and make money through actual sales of products can occupy this shell."
You all are probably wondering how many shares we have still. That will be disclosed in the filings, which will probably be presented 30 seconds before the change in ownership. We're pretending to reopen so as to entice new buyers and up our exit fee. Hopefully we all come out a little ahead, so please don't be mad at us
Forward looking and rearview revising statements...
blah blah blah blah
Now that I've written this satirical version, I'm not sure it any less comical than the original PR which you can find at https://www.issuewire.com/spooz-inc-to-become-compliant-with-otc-markets-reporting-obligations-1699560188962288
glta
wow... just wow
It will be interesting to see if the buying machine reactivates at some point.
I still think the PR from Paul Strickland was strange. If he was getting into crypto, hopefully it was on the short side. Look out below. Bitscam and Dogecrap. XLM is the only stellar crypto that has my money.
COVID play- $ARFXF ProMIS Neurosciences just announced commercialization of its highly selective and specific serology test for COVID antibodies.
It can measure your response to infection or vaccination and the level of immunity you have to the different variants.
The company market cap is $50M. The annual COVID serology test market is in the $1-2B range. There are some competitors out there, but a lot of the products on the market are crap. So their market penetration could be high.
This company also has some awesome products in the pipe of Alzheimer's treatment, and that market is massive and largely unmet.
more info at:
https://promisneurosciences.com/news/promis-neurosciences-initiates-commercialization-of-covid-19-serology-assay/
and
covidimmunitypassport.com
$ARFXF announces commercialization of new COVID antibody test
ProMIS initiates commercialization of COVID-19 assay
ProMIS Neurosciences initiates commercialization of COVID-19 serology assay
TORONTO and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it has initiated commercialization of its COVID-19 serology assay and has appointed Owen Dempsey to lead the commercialization program.
Owen’s professional work for the past 25 years has been to build companies founded to discover and commercialize antibodies in applications including life science research, pharmaceutical drug discovery, clinical diagnostics and therapeutic treatment of cancer, AIDS and other serious illness. He has led private, venture-backed as well as NASDAQ-listed companies and is a past board member of ALDA, the Analytical, Life Science & Diagnostics Association.
“I am delighted to lead this opportunity on behalf of ProMIS Neurosciences,” stated Owen Dempsey. “Our serology assay commercialization efforts will be targeting the need for a highly accurate test to detect, quantify and characterize antibodies against the virus causing COVID-19, either as a consequence of contracting the viral disease or in response to vaccination. Our initial focus will be on commercialization to the medical and public health community, vaccine developers, pharmaceutical companies, governmental agencies and other organizations.”
This advanced serology test developed by ProMIS Neurosciences measures not only serum antibodies to SARS-CoV-2, the novel coronavirus causing COVID-19, but also their protective activity against infection. The assay simultaneously assesses antibody levels in the blood of study participants and their neutralizing activity against the original strain of SARS-CoV-2 as well as emerging variants. Additional variants can be added to the assay as they are identified. The assay utilizes an advanced, high-throughput, sensitive and accurate surface plasmon resonance (SPR) technology as opposed to traditional ELISA (enzyme-linked immunosorbent assay) methods.
In commercializing an advanced serology testing platform, we aim to meet the needs of the medical community and investigators in academia, industry and government working to assess response and durability of response to vaccines as well as to monitor and assess antibody response to emerging strains of the virus.. As reported in the scientific literature, our accurate and sensitive format is capable of measuring neutralizing antibodies that inhibit coronavirus RBD binding to the human ACE2 receptor. This provides a powerful surrogate measure of antibody immunity without the need for live virus or pseudovirus formats. This and similar collaborative efforts may help to guide the need for boosters or modified vaccines addressing emerging strains and will inform the medical community’s preparedness to meet similar public threats to global health in the years ahead.
It is important to note, as stated above that the initial marketing and commercialization of the assay will be directed only to organizations such as vaccine manufacturers, pharmaceutical companies and government organizations at the national and state/provincial level. The assay is not currently available to private individual consumers or the general public.
$ARFXF news on COVID antibody test launch
ProMIS initiates commercialization of COVID-19 assay
ProMIS Neurosciences initiates commercialization of COVID-19 serology assay
TORONTO and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it has initiated commercialization of its COVID-19 serology assay and has appointed Owen Dempsey to lead the commercialization program.
Owen’s professional work for the past 25 years has been to build companies founded to discover and commercialize antibodies in applications including life science research, pharmaceutical drug discovery, clinical diagnostics and therapeutic treatment of cancer, AIDS and other serious illness. He has led private, venture-backed as well as NASDAQ-listed companies and is a past board member of ALDA, the Analytical, Life Science & Diagnostics Association.
“I am delighted to lead this opportunity on behalf of ProMIS Neurosciences,” stated Owen Dempsey. “Our serology assay commercialization efforts will be targeting the need for a highly accurate test to detect, quantify and characterize antibodies against the virus causing COVID-19, either as a consequence of contracting the viral disease or in response to vaccination. Our initial focus will be on commercialization to the medical and public health community, vaccine developers, pharmaceutical companies, governmental agencies and other organizations.”
This advanced serology test developed by ProMIS Neurosciences measures not only serum antibodies to SARS-CoV-2, the novel coronavirus causing COVID-19, but also their protective activity against infection. The assay simultaneously assesses antibody levels in the blood of study participants and their neutralizing activity against the original strain of SARS-CoV-2 as well as emerging variants. Additional variants can be added to the assay as they are identified. The assay utilizes an advanced, high-throughput, sensitive and accurate surface plasmon resonance (SPR) technology as opposed to traditional ELISA (enzyme-linked immunosorbent assay) methods.
In commercializing an advanced serology testing platform, we aim to meet the needs of the medical community and investigators in academia, industry and government working to assess response and durability of response to vaccines as well as to monitor and assess antibody response to emerging strains of the virus.. As reported in the scientific literature, our accurate and sensitive format is capable of measuring neutralizing antibodies that inhibit coronavirus RBD binding to the human ACE2 receptor. This provides a powerful surrogate measure of antibody immunity without the need for live virus or pseudovirus formats. This and similar collaborative efforts may help to guide the need for boosters or modified vaccines addressing emerging strains and will inform the medical community’s preparedness to meet similar public threats to global health in the years ahead.
It is important to note, as stated above that the initial marketing and commercialization of the assay will be directed only to organizations such as vaccine manufacturers, pharmaceutical companies and government organizations at the national and state/provincial level. The assay is not currently available to private individual consumers or the general public.
Trade of the Year?
$ARFXF Current market cap is only $50M
About to launch their 'best in class' COVID serology test on June 1st
Each test kit costs $495, so if they sell 2 million tests at 25% profit, the P/E ratio would be 0.2 (versus 10-20 for the industry)
So who wants in on a potential 100-bagger?
https://covidimmunitypassport.com/product/premium-kit-covid-19-antibodies-testing/
T minus 7 days to launch!!!
PMN.TO (ARFXF in US) is looking really good based on solid news releases over the last 2 months as well as due diligence shared on stockhouse board
They have a 50-50 JV called immusafe that is about to launch its first product- a COVID serology test that claims to be the best in class. details at covidimmunitypassport.com
They are scaling up production of highly selective antibody for Alzheimer's treatment that is a lot better than Biogen's aducanumab. They should start PhI trials this year and recently attracted a $7M investment from the owners of the Boston Red Sox and New England Patriots who have close connections to Alzheimer's cure development. The director of their scientific advisory panel is a bigshot from Harvard.
As far as pennies go- this one is closer to gold than copper. do your own research. These are my personal opinions and not financial advice.
promisneurosciences.com